ReviewBritish journal of pharmacology2004
Cannabinoids and intestinal motility: welcome to CB2 receptors.
Review in British journal of pharmacology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 42 citations in OpenAlex.
- Detection of Cannabinoid Receptor Expression by Endometriotic Lesions in Women with Endometriosis as an Alternative to Opioid-Based Pain Medication.Journal of immunology research · 2022Article
- Epigenetic Regulation of Cannabinoid-Mediated Attenuation of Inflammation and Its Impact on the Use of Cannabinoids to Treat Autoimmune Diseases.International journal of molecular sciences · 2021Review
- Cannabinoid and Cannabinoid-Related Receptors in the Myenteric Plexus of the Porcine Ileum.Animals : an open access journal from MDPI · 2021Article
- Cannabis and Cannabis Derivatives for Abdominal Pain Management in Inflammatory Bowel Disease.Medical cannabis and cannabinoids · 2021Review
- Lenabasum for Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis.Arthritis & rheumatology (Hoboken, N.J.) · 2020Article
- Localization of cannabinoid and cannabinoid related receptors in the cat gastrointestinal tract.Histochemistry and cell biology · 2020Article
- Emerging Promise of Cannabinoids for the Management of Pain and Associated Neuropathological Alterations in Alzheimer's Disease.Frontiers in pharmacology · 2020Review
- Role of cytochrome P450 polymorphisms and functions in development of ulcerative colitis.World journal of gastroenterology · 2019Review
- Localization of cannabinoid receptors CB1, CB2, GPR55, and PPARα in the canine gastrointestinal tract.Histochemistry and cell biology · 2018Article
- The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations.British journal of pharmacology · 2017Review
- Metabolism of Anandamide by Human Cytochrome P450 2J2 in the Reconstituted System and Human Intestinal Microsomes.The Journal of pharmacology and experimental therapeutics · 2016Article
- Cannabis, a complex plant: different compounds and different effects on individuals.Therapeutic advances in psychopharmacology · 2012Article
- Small intestinal cannabinoid receptor changes following a single colonic insult with oil of mustard in mice.Frontiers in pharmacology · 2010Article
- The silent symptom early satiety: a forerunner of distinct phenotypes of anorexia/cachexia syndromes.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2006Review
- The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract.Journal of molecular medicine (Berlin, Germany) · 2005Review
- Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delta(9)-tetrahydrocannabinol (the active ingredient of marijuana), as well as endogenous and synthetic cannabinoids, exert many biological functions by activating two types of cannabinoid receptors, CB(1) receptors (expressed by central and peripheral neurons) and CB(2) receptors (that occur mainly in immune cells). Convincing evidence has accumulated in recent years that cannabinoids inhibit gastric and intestinal motility through activation of enteric CB(1) receptors. However, a report in this issue of British Journal of Pharmacology has highlighted the possibility that CB(2) receptors in the rat intestine could contribute to reducing the increase of intestinal motility induced by an endotoxic inflammation. By minimizing the adverse psychotropic effects associated with brain cannabinoid receptors, the CB(2) receptor represents a new molecular target for the treatment of motility disorders associated with intestinal inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.